There is no human 5 amino 1mq dosage, because there has never been a human study. The mouse work used three injections under the skin, every day, of something sold as a capsule.
The short version
No human trial of 5-amino-1MQ exists. The registry lists zero. The mouse study gave 20 mg/kg per shot, three shots a day, about 34 mg/kg in total, for 11 days. Nine mice. They lost about 5% of body weight.
5-amino-1MQ is not a peptide. It is a small quinolinium molecule that blocks nicotinamide N-methyltransferase, an enzyme fat tissue makes more of when it is overfed. It sits in peptide catalogs because of the company it keeps, not because of what it is.
What the 5-amino-1MQ studies administered
| Study | Species | Dose | Route | Duration | n |
|---|---|---|---|---|---|
| Neelakantan et al., 2018 | Mouse (diet-induced obese, male C57Bl/6) | 20 mg/kg per injection, about 34 mg/kg per day | Subcutaneous, three injections daily | 11 days | 9 per cohort |
| Neelakantan et al., 2019 | Mouse (aged, post-injury) | 5 and 10 mg/kg | Not stated in the record | 1 week or 3 weeks after injury | — |
| Dimet-Wiley et al., 2022 | Mouse (diet-induced obese, with low-fat diet) | — | — | — | — |
A dash means we have no sourced figure for that cell and have not estimated one.
Three studies, one full dose row. That is the whole in-vivo record for this compound as far as we could verify it.
- Species: mouse, in every row.
- Route: subcutaneous injection where it is stated at all.
- Design: none of the three is a dose-finding study.
Has 5-amino-1MQ been tested in humans?
No, and this one is easy to check. We queried the clinical-trials registry for 5-amino-1MQ, for 5-amino-1-methylquinolinium and for NNMT inhibitors generally. Zero studies came back for each.
The published literature on the exact compound name runs to three papers. One mouse microbiome study, one mouse bladder-cancer study, one HeLa cell study. There is no human trial of any kind, of any design, at any dose.
Three injections a day, for a capsule
The 2018 study is the one everything rests on, and its regimen is worth reading carefully. Mice received three separate subcutaneous injections a day, 20 mg/kg each, totalling about 34 mg/kg of the parent compound daily, for 11 days.
Mice in the treatment cohort received three SC injections of the NNMT inhibitor 5-amino-1MQ at a dose of 20 mg/kg/injection for a total dose of ~34 mg/kg/day of the parent compound for 11 days.
Neelakantan et al., Biochemical Pharmacology, 2018The result was a weight loss of 2.0 grams, roughly 5.1% of body weight, with a 35% fall in the mass and size of epididymal white fat. For a 17-week-old obese mouse in 11 days, that is a real effect.
5-Amino-1MQ
The quinolinium NNMT inhibitor studied in the mouse literature reviewed here. Research use only — supplied with a batch-matched certificate of analysis.
Two things about that regimen do not carry over. The route is subcutaneous injection, three times daily, and the compound is overwhelmingly sold and discussed as an oral capsule. Nothing in the published record establishes what an oral dose would need to be.
The arithmetic, if you insist on doing it. 34 mg/kg a day multiplied by 70 kg is about 2.4 grams daily. That figure is absurd, and its absurdity is the method's fault rather than the compound's. Surface-area scaling divides a mouse dose by 12.3, which lands near 190 mg a day — and even that is only where a Phase 1 safety trial would start, before a further safety factor.
What is established
- The target is real. Knocking down NNMT protected mice against diet-induced obesity, in a 2014 Nature paper that predates the inhibitor.
- The inhibitor reaches it. 5-amino-1MQ is membrane-permeable and selective, which is what the 2018 paper set out to demonstrate.
- The muscle work used far less. The 2019 aged-muscle study ran 5 and 10 mg/kg, a third to a sixth of the obesity regimen, for different endpoints.
Treatment of DIO mice with the NNMT inhibitor resulted in a substantial ~35% decrease in the mass and size of the EWAT.
Neelakantan et al., Biochemical Pharmacology, 2018None of that is a dose for a person. A validated target and a permeable inhibitor are the two things you need before running a human trial, not substitutes for having run one.
What if you already have a number?
5-amino-1MQ is a small molecule sold by weight, so vial arithmetic behaves the same way it does for a peptide.
Turning a figure into a syringe volume is arithmetic, and the peptide calculator does it from the vial strength and the volume of diluent. That part always works.
Which is the trap. A calculator converts an unsourced number as cleanly as a sourced one. The output looks equally precise either way. The input is the part with no published source.
What is checkable
Identity by mass is straightforward at molecular weight 159, and purity is a number on a certificate. Because this is a small molecule rather than a peptide, the relevant analysis is the same in principle but the impurity profile is different.
How to read a COA, the complete guide, the fat-loss research and where to buy 5-amino-1MQ cover the rest. The peptide dosage chart places it in the library.
5-Amino-1MQ
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- No human trial of 5-amino-1MQ has been registered or published. The registry returns zero studies.
- The mouse regimen was 20 mg/kg per injection, three times a day, about 34 mg/kg daily, for 11 days.
- Nine mice per cohort lost roughly 5.1% of body weight, with a 35% fall in white fat mass.
- The route was subcutaneous injection. The product is sold as an oral capsule.
- The aged-muscle work used 5 and 10 mg/kg, far below the obesity regimen.
What we're watching
A registered Phase 1 would change this page entirely, and this is a compound where one is plausible: the target has a Nature paper behind it and the inhibitor is orally tractable in principle.
An oral bioavailability study in any species would be nearly as useful. Right now the only administered route in the record is one nobody uses.
Frequently asked questions
What dose of 5-amino-1MQ was used in the mouse study?
20 mg/kg per injection, three subcutaneous injections a day, for a total of about 34 mg/kg a day, over 11 days. Nine mice were in the treated group.
Has 5-amino-1MQ been tested in humans?
No. The clinical-trials registry returns zero studies for 5-amino-1MQ, 5-amino-1-methylquinolinium or NNMT inhibitors, and the published literature on the compound is three papers, all preclinical.
How much weight did the mice lose?
About 5.1% of body weight over 11 days, roughly 2 grams, with a 35% fall in the mass and size of epididymal white fat.
Is 5-amino-1MQ a peptide?
No. It is a small quinolinium molecule with a molecular weight of about 159, which is why it is membrane-permeable and why it appears in capsules rather than vials.
Can the mouse dose be scaled to a person?
Not by body weight. 34 mg/kg a day would be about 2.4 grams for a 70 kg adult. Surface-area scaling divides a mouse dose by 12.3, which would give roughly 190 mg a day — and that is a Phase 1 starting estimate, not a dose.
References
- Neelakantan, H., Vance, V., Wetzel, M. D., et al. (2018). Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high-fat diet-induced obesity in mice. Biochemical Pharmacology, 147, 141–152. https://doi.org/10.1016/j.bcp.2017.11.007
- Neelakantan, H., Brightwell, C. R., Graber, T. G., et al. (2019). Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical Pharmacology, 163, 481–492. https://doi.org/10.1016/j.bcp.2019.02.008
- Dimet-Wiley, A., Wu, Q., Wiley, J. T., et al. (2022). Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Scientific Reports, 12(1), 484. https://doi.org/10.1038/s41598-021-03670-5
- Kraus, D., Yang, Q., Kong, D., et al. (2014). Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature, 508(7495), 258–262. https://doi.org/10.1038/nature13198
- Pissios, P. (2017). Nicotinamide N-methyltransferase: More than a vitamin B3 clearance enzyme. Trends in Endocrinology & Metabolism, 28(5), 340–353. https://doi.org/10.1016/j.tem.2017.02.004
- Akar, S., Duran, T., Azzawri, A. A., Koçak, N., Çelik, Ç., & Yıldırım, H. (2021). Small molecule inhibitor of nicotinamide N-methyltransferase shows anti-proliferative activity in HeLa cells. Journal of Obstetrics and Gynaecology, 41(8), 1240–1245. https://doi.org/10.1080/01443615.2020.1854696
The absence of a human trial was checked directly against ClinicalTrials.gov, for the compound name and for NNMT inhibitors as a class.